Matthew Haney - Barclays Capital VP Devel
| CAPD Etf | USD 84.80 65.43 337.79% |
| Age | 46 |
| Web | http://canna-powder.com |
Barclays Capital Management Efficiency
The company has return on total asset (ROA) of (3.4756) % which means that it has lost $3.4756 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (17.8346) %, meaning that it created substantial loss on money invested by shareholders. Barclays Capital's management efficiency ratios could be used to measure how well Barclays Capital manages its routine affairs as well as how well it operates its assets and liabilities.Barclays Capital currently holds 550 K in liabilities. Barclays Capital has a current ratio of 0.41, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Barclays Capital until it has trouble settling it off, either with new capital or with free cash flow. So, Barclays Capital's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Barclays Capital sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Barclays to invest in growth at high rates of return. When we think about Barclays Capital's use of debt, we should always consider it together with cash and equity.
Similar Fund Executives
| Showing other executives | One Year Return | ||
| JohnPaul Felter | Humana Inc | 41 | |
| Wayne Frederick | Humana Inc | 49 | |
| Nwando Olayiwola | Humana Inc | N/A | |
| Tom Holmes | Amylyx Pharmaceuticals | N/A | |
| Marcy Klevorn | Humana Inc | 61 | |
| Sue Schick | Humana Inc | N/A | |
| Jorge Mesquita | Humana Inc | 59 | |
| Justin Klee | Amylyx Pharmaceuticals | 33 | |
| T Wheatley | Humana Inc | 53 | |
| Raquel Bono | Humana Inc | 64 | |
| Margaret MBA | Amylyx Pharmaceuticals | 59 | |
| Carolyn Tandy | Humana Inc | N/A | |
| Heather Cox | Humana Inc | 50 | |
| Joshua Cohen | Amylyx Pharmaceuticals | 32 | |
| John Garratt | Humana Inc | 52 | |
| Chris Aiello | Amylyx Pharmaceuticals | N/A | |
| Timothy Wheatley | Humana Inc | 56 | |
| PharmD PharmD | Humana Inc | 54 | |
| Shauna Horvath | Amylyx Pharmaceuticals | N/A | |
| Ann Lee | Prime Medicine, Common | 62 | |
| James MBA | Amylyx Pharmaceuticals | 57 | |
Management Performance
| Return On Equity | -17.83 | |||
| Return On Asset | -3.48 |
Barclays Capital Money Managers
| Aharon Levinas, CTO, Director | ||
| Oded Gilboa, Chief Officer | ||
| Matthew Haney, VP Devel | ||
| Rafi Ezra, CoFounder Ltd | ||
| Shai Cohen, CEO, Director |
Barclays Etf Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right etf is not an easy task. Is Barclays Capital a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -17.83 | |||
| Return On Asset | -3.48 | |||
| Shares Outstanding | 12.8 M | |||
| Shares Owned By Insiders | 96.65 % | |||
| Price To Book | 34.65 X | |||
| Net Income | (2.77 M) | |||
| Cash And Equivalents | 205.21 K | |||
| Cash Per Share | 0.02 X | |||
| Total Debt | 550 K | |||
| Current Ratio | 0.42 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Barclays Capital offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Barclays Capital's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Barclays Capital Etf. Outlined below are crucial reports that will aid in making a well-informed decision on Barclays Capital Etf:Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any etf could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
The market value of Barclays Capital is measured differently than its book value, which is the value of Barclays that is recorded on the company's balance sheet. Investors also form their own opinion of Barclays Capital's value that differs from its market value or its book value, called intrinsic value, which is Barclays Capital's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Barclays Capital's market value can be influenced by many factors that don't directly affect Barclays Capital's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Barclays Capital's value and its price as these two are different measures arrived at by different means. Investors typically determine if Barclays Capital is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Barclays Capital's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.